{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:13:23Z","timestamp":1788513203183,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Chronic myeloid leukaemia in chronic phase (CML\u2010CP) treatment recommendations have changed substantially in recent years. The ADAPT 2.0 survey aimed to provide an updated understanding of CML\u2010CP management in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This healthcare professional (HCP) survey, conducted between December 2023 and June 2024, assessed treatment goals, choice of tyrosine kinase inhibitors (TKIs), unmet needs and approaches to treatment\u2010free remission (TFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      UK CML\u2010CP practise is generally aligned with the contemporary guidelines for CML management. Key treatment goals were major molecular response (54%\u201377% across treatment lines) and deep molecular response (5%\u201346%). The main factors influencing first\u2010line (1\u2009L) TKI selection were treatment guidelines (97%), comorbidities (90%) and TFR as a treatment goal (82%). Therapy switch after one warning European LeukemiaNet (ELN) 2020 response was rare (10% vs. 56% in patients with &gt;\u20091 warning response and 100% in failure response).\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      mutation analysis was less common after one warning response versus &gt;\u20091 warning response (54% vs. 82%). TKI toxicity, resistance, intolerance and T315I mutation management were key unmet needs in later treatment lines; achieving and maintaining TFR were key unmet needs in 1\u2009L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ADAPT 2.0 survey highlights potential areas of improvement in current CML\u2010CP management in the UK.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70226","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:59:57Z","timestamp":1782403197000},"page":"1072-1080","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adapting\n                    <scp>UK<\/scp>\n                    Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The\n                    <scp>ADAPT<\/scp>\n                    2.0 Survey"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-8220","authenticated-orcid":false,"given":"Dragana","family":"Milojkovic","sequence":"first","affiliation":[{"name":"Centre for Haematology, Faculty of Medicine, Imperial College London, and Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton  Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketul","family":"Desai","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Frewin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Cancer Research UK \u201cChronic Myeloid Leukaemia (CML) Incidence by Gender and UK Country \u201daccessed May 19 2026 https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/leukaemia\u2010cml\/incidence#heading\u2010Zero."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2023.102421"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-023-00703-w"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16971"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02048-y"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_9_11_1","unstructured":"M.Copland N. C. P.Cross B.Huntly et\u00a0al. \u201cA Survey of Healthcare Professionals in the United Kingdom to Describe Current Pathways and Management Practices in Chronic Myeloid Leukaemia: The ADAPT CML Survey \u201d2021 European Haematology Association Annual Meeting."},{"issue":"2","key":"e_1_2_9_12_1","article-title":"A Survey of Healthcare Professionals in the United Kingdom to Describe Current Pathways and Management Practices in Chronic Myeloid Leukaemia: The ADAPT CML Survey","volume":"5","author":"Copland M.","year":"2021","journal-title":"HemaSphere"},{"key":"e_1_2_9_13_1","unstructured":"EPHMRA \u201cEPHMRA Code of Conduct \u201daccessed April 22 2026 https:\/\/www.ephmra.org\/sites\/default\/files\/2024\u201009\/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf."},{"key":"e_1_2_9_14_1","unstructured":"ESOMAR \u201cESOMAR Guideline on the Mutual Rights and Responsibilities of Researchers and Client \u201daccessed April 22 2026 https:\/\/shop.esomar.org\/uploads\/public\/knowledge\u2010and\u2010standards\/codes\u2010and\u2010guidelines\/ESOMAR_Codes\u2010and\u2010Guidelines_Mutual\u2010Rights\u2010And\u2010Responsibilities\u2010Of\u2010Researchers\u2010And\u2010Clients.pdf."},{"key":"e_1_2_9_15_1","unstructured":"(BHBIA) BHBIA \u201cLegal and Ethical Guidelines \u201daccessed April 22 2026 https:\/\/www.bhbia.org.uk\/guidelines\u2010and\u2010legislation\/legal\u2010and\u2010ethical\u2010guidelines."},{"key":"e_1_2_9_16_1","unstructured":"Association I \u201cCode of Standards and Ethics for Market Research and Data Analytics \u201daccessed April 22 2026 https:\/\/www.insightsassociation.org\/Portals\/INSIGHTS\/Insights%20Association%20Code%20of%20Standards_November%202023_v2.pdf."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.261"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30094-8"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.6910"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-010-0050-1"},{"issue":"2","key":"e_1_2_9_21_1","first-page":"597","article-title":"Improving Chronic Myeloid Leukemia Management and Quality of Life: Patient and Physician Survey on Unmet Needs From the CML SUN Survey","volume":"111","author":"Lang F.","year":"2026","journal-title":"Haematologica"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.11.005"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S92125"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.02.002"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0958-6"},{"issue":"3","key":"e_1_2_9_27_1","article-title":"HSR25\u2010174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors\u2014Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study","volume":"23","author":"Flynn K. E.","year":"2025","journal-title":"Journal of the National Comprehensive Cancer Network"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70226","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70226","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:22:39Z","timestamp":1788510159000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/ejh.70226"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70226","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"2026-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}